Compare HRTG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | GERN |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.5M | 808.3M |
| IPO Year | 2014 | N/A |
| Metric | HRTG | GERN |
|---|---|---|
| Price | $21.97 | $1.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $33.50 | $2.17 |
| AVG Volume (30 Days) | 561.2K | ★ 13.1M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $847,330,000.00 | N/A |
| Revenue This Year | $7.50 | $26.91 |
| Revenue Next Year | $6.74 | $43.75 |
| P/E Ratio | $17.83 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $16.83 | $1.04 |
| 52 Week High | $31.98 | $2.01 |
| Indicator | HRTG | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 39.38 | 31.48 |
| Support Level | $20.98 | $1.05 |
| Resistance Level | $24.65 | $1.30 |
| Average True Range (ATR) | 0.88 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 37.16 | 19.44 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.